Please login to the form below
allergy
This page shows the latest allergy news and features for those working in and with pharma, biotech and healthcare.
FDA grants priority review for AZ, Amgen’s tezepelumab for asthma
Clinically meaningful reductions in AAER were observed in tezepelumab-treated patients regardless of allergy status and fractional exhaled nitric oxide (FeNO) level – biomarkers used by clinicians to inform treatment options. ... Tezepelumab has
Latest news
-
Nestlé and Seres announce new partnership for C.diff microbiome therapeutic
difficile infection,” added Greg Behar, CEO of Nestlé Health Science. In September 2020, Nestlé furthered its push into pharma with the acquisition of allergy specialist Aimmune Therapeutics in a deal worth ... Aimmune’s Palforzia became the first
-
US announces $3bn funding boost for antiviral COVID-19 treatments
The Antiviral Programme for Pandemics will be implemented by the US Department of Health and Human Services (HHS), including the National Institute of Allergy and Infectious Diseases (NIAID), the Biomedical Advanced
-
AZ, Amgen file first-in-class asthma drug with the FDA
Clinically meaningful reductions in AAER were observed in tezepelumab-treated patients regardless of allergy status and fractional exhaled nitric oxide (FeNO) level – biomarkers used by clinicians to inform treatment options.
-
Roche, Regeneron’s COVID-19 antibody cocktail cuts infection risk
The phase 3 2069A trial – run jointly with the US National Institute of Allergy and Infectious Diseases (NIAID) – evaluated the ability of REGEN-COV (casirivimab with imdevimab) to reduce the risk
-
AZ publishes primary analysis for COVID-19 vaccine, showing slightly lower efficacy of 76%
Shortly after that, the US data and safety monitoring board (DSMB) notified the US National Institute of Allergy and Infectious Diseases (NIAID), the Biomedical Advanced Research and Development Authority (BARDA) and
Nestlé and Seres announce new partnership for C.diff microbiome therapeutic
US announces $3bn funding boost for antiviral COVID-19 treatments
AZ, Amgen file first-in-class asthma drug with the FDA
Roche, Regeneron’s COVID-19 antibody cocktail cuts infection risk
More from news
Approximately 17 fully matching, plus 230 partially matching documents found.
Latest Intelligence
-
The pandemic preparedness paradox
In the United States, the National Institute of Allergy and Infectious Diseases alone spends $6bn annually in the labs of some of the best and brightest scientists in the world.
-
The search for effective drug treatments for COVID-19
medicine. to contribute to the medical response in public health emergencies. The EUA was based on then available data from two global clinical trials – the National Institute for Allergy and Infectious
-
Exploring the potential of eosinophils
when starting his research career in Southampton, UK before going on to be Professor of Allergy and Respiratory Medicine at Southampton University. ... Working as a clinician at this time meant he was caring for patients with allergies and asthma, in
-
As COVID-19 takes over the world, biopharma fights back
I don’t think the ongoing trials will tell us a lot,” said H Clifford Lane, clinical director at the National Institutes of Allergy and Infectious Diseases (NIAID).
-
Cortellis Drugs to Watch in 2020 report
This year’s list also highlights three first-in class medicines compared with last year’s list, which contained only one first-in-class medicine, peanut allergy vaccine Palforzia.
The pandemic preparedness paradox
The search for effective drug treatments for COVID-19
Exploring the potential of eosinophils
As COVID-19 takes over the world, biopharma fights back
Cortellis Drugs to Watch in 2020 report
More from intelligence
Approximately 1 fully matching, plus 25 partially matching documents found.
Latest appointments
-
New faces at Prime Global, Swordfish Advertising and Wilmington Healthcare
Before AstraZeneca, she worked for GlaxoSmithKline for four years in a number of roles, including therapy specialist for its allergy portfolio.
-
ALK-Abello appoints Søren Jelert as CFO
He will be based at the company’s headquarters in Denmark. Dansih allergy immunotherapy company ALK-Abello has appointed Søren Jelert as its new chief financial officer, a role that sees ... to become a truly global allergy company.”.
-
Cytovation expands management team
Grego is currently chief executive officer of Spire Bioventures, a global healthcare consultancy and mentoring service, and has previously held a number of management positions at Spanish allergy specialist Laboratorios LETI.
-
Lars Dreiøe joins Sobi in senior quality and compliance role
He will join the firm in January from Danish allergy vaccine company ALK Abelló, where he was international head of quality.
-
ARC names chairman and member of the board
ARC is a privately held biopharma company developing desensitisation treatments for food allergies. ... Iwicki said: “ARC is working to address a very compelling therapeutic area and provide an option to those dealing with food allergies.
New faces at Prime Global, Swordfish Advertising and Wilmington Healthcare
ALK-Abello appoints Søren Jelert as CFO
Cytovation expands management team
Lars Dreiøe joins Sobi in senior quality and compliance role
ARC names chairman and member of the board
More from appointments
Approximately 0 fully matching, plus 15 partially matching documents found.
Latest from PMHub
-
5 ways that lockdowns and restrictions could be affecting our allergies
Allergies are common, with around 44% of UK adults suffering from at least one allergy. ... For Allergy Awareness week 2021, we explored some of the significant ways that this may have impacted our experiences with allergies.
-
Lifesaving QR Code Wearable Launched to Help Emergency Services
Whilst a mi-SOS user can inform the public about underlying health conditions, a user can also update their profile with additional details such as allergies, critical care plans, COVID-19
-
Wilmington Healthcare appoints new consultants
for its allergy portfolio.
-
Corporate event food. How to get it right
Vegetarian. Vegan. Gluten-free. Peanut allergies. Lactose intolerant. Diabetic. Kosher. Halal. To keep everyone happy, be sure to ask your delegates if they have any dietary requirements ASAP.
-
Blog: The Future of Food Allergy? The Emergence of Targeted Allergy Treatments
Research Analyst Rachel Arthurs explores how public exposure to the complications of food allergy has affected attitudes toward treatment. ... This is not an isolated incident, but a constant fear and source of anxiety for allergy sufferers all over the
5 ways that lockdowns and restrictions could be affecting our allergies
More from PMHub
Approximately 4 fully matching, plus 13 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
-
Digital strategist
-
Competitive
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- FREELANCE (Outside IR35) Opportunities for this week below!!!
-
Superb Day Rate
- Client Services Director +, Remote or London – Leadership Opport...
-
Highly Competitive Salary, Bonus &Benefits
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
-
Digital project manager
-
Competitive
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
-
Digital account director
-
Competitive
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- Bayer’s BlueRock Therapeutics gains FDA fast track for Parkinson’s disease cell therapy
- Israel study suggests Pfizer/BioNTech vaccine is less effective against Delta variant
- GSK reveals plans for £400m R&D facility expansion in England
- EU approves bluebird bio’s CALD gene therapy Skysona
- NHS earmarks £340m for new medicines fund to fast-track ‘innovative’ treatments
- FDA advisory committee votes against approval of AZ, FibroGen's roxadustat
- Pfizer and Arvinas announce $1bn deal for investigational oral protein degrader
- Roche engaged in talks with FDA for Alzheimer’s drug candidate
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- The future of work has been just around the corner for some time...
- Investigating the Complexities of the Canadian & Global Health Systems
- Impetus Digital Overview
- Onyx Health Launch Creative Studio After Record Year
- Kriya Therapeutics raises $100m to further develop gene therapies with ‘broader applications’
- Lilly and Banner Alzheimer’s Institute collaborate on donanemab prevention trial
- Positive prospects for pharma in Latin America
- Pfizer/BioNTech, AZ vaccines effective against Delta COVID-19 variant after two doses
- Biosimilars in China
Latest intelligence
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
- The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
- Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
- Virtual Speaker Program: A Customer Story
- Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....
